At study entry, patients demonstrated immune compromise consistent with prior standard of care, including radiation and alkylating chemotherapy. The baseline mean absolute lymphocyte count (ALC) was ...

Impact of venous thromboembolism on survival in multiple myeloma patients receiving bispecific antibody therapy: Insights from real-world data. Risk of second primary hematological malignancy post CAR ...

(A) Principal component analysis (PCA) of lymphocyte subsets and factors such as age in Control, LC, and LC-PTB groups, and the joint analysis of LC & LC-PTB. PC1 and PC2 represent the first and ...

Measuring the lymphocytes — white blood cells that fight infection — in a patient’s blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to ...

While Epogen and Neupogen addresses anemia and neutropenia, no therapy has existed for the treatment of lymphopenia until ANKTIVA® –The Cancer BioShield. Landmark overall survival benefit (P-value ...

Please provide your email address to receive an email when new articles are posted on . Lymphopenia at diagnosis or during follow-up can predict OS among patients with multiple myeloma. Researchers ...

Impact of metformin on the efficacy of immune checkpoint inhibitors in metastatic melanoma: A large-scale retrospective analysis. Summary of the primary and secondary analysis.

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access ...